Meningococcal vaccine group C conjugate - GlaxoSmithKline

Drug Profile

Meningococcal vaccine group C conjugate - GlaxoSmithKline

Alternative Names: MenC-CRM conjugate vaccine; Meningococcal C-CRM197 conjugate vaccine; Menjugate

Latest Information Update: 09 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Meningococcal group C infections

Most Recent Events

  • 04 Jan 2018 inVentiv Health has merged with INC Research to form Syneos Health
  • 31 Aug 2017 GlaxoSmithKline completes a phase I trial for Meningococcal group C infections (In volunteers) in Germany (IM) (NCT02639351)
  • 01 Mar 2016 GlaxoSmithKline initiates a phase I trial for Meningococcal group C infections (In volunteers) in Germany (IM) (NCT02639351)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top